New approach methodologies for human-relevant toxicology: from mechanistic evidence to regulatory decision-making

New Approach Methodologies (NAMs) are transforming toxicology from a predominantly animal-based, apical endpoint paradigm toward a human relevant, mechanistically informed, exposure driven and data integrated framework for risk assessment. Rather than serving as simple one-to-one replacements for conventional animal studies, NAMs comprise a broad toolbox of in silico, in chemico, in vitro, ex vivo, omics-based, exposure and kinetic modelling approaches that can be combined within Integrated Approaches to Testing and Assessment (IATA), Adverse Outcome Pathway (AOP) frameworks and next generation risk assessment (NGRA). This review critically evaluates the scientific basis, technological platforms, translational applications, advantages, limitations and regulatory readiness of NAMs in modern toxicology. Particular emphasis is placed on the integration of human cell-based systems, microphysiological systems, organoids, transcriptomics, metabolomics, physiologically based kinetic (PBK) modelling, in vitro to in vivo extrapolation (IVIVE), exposure bioactivity relationships and scientific confidence frameworks. Current developments from the European Food Safety Authority (EFSA), European Chemicals Agency (ECHA), European Medicines Agency (EMA), Organisation for Economic Co-operation and Development (OECD), United States Food and Drug Administration (FDA), Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), Health Canada and the European Commission are discussed to highlight the increasing regulatory momentum toward fit-for-purpose qualification and reduced animal use. The review concludes that successful implementation of NAMs will require clear problem formulation, standardized reporting, robust quality control, uncertainty characterization, interoperable data infrastructures and international harmonization.

Authors

Institutions

Publication Details

Journal
Journal of Research in Pharmacy
Published
2026-11-12
DOI
https://doi.org/10.12991/jrespharm.1989640
Primary Topic
Animal testing and alternatives
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

New approach methodologies for human-relevant toxicology: from mechanistic evidence to regulatory decision-making

Zeynep Aydın, Yüksel Çetin, Ece Sabuncu, Gülşah Esen
Journal of Research in Pharmacy
Animal testing and alternatives
article

New approach methodologies for human-relevant toxicology: from mechanistic evidence to regulatory decision-making

Zeynep Aydın, Yüksel Çetin, Ece Sabuncu, Gülşah Esen
article en

Abstract

New Approach Methodologies (NAMs) are transforming toxicology from a predominantly animal-based, apical endpoint paradigm toward a human relevant, mechanistically informed, exposure driven and data integrated framework for risk assessment. Rather than serving as simple one-to-one replacements for conventional animal studies, NAMs comprise a broad toolbox of in silico, in chemico, in vitro, ex vivo, omics-based, exposure and kinetic modelling approaches that can be combined within Integrated Approaches to Testing and Assessment (IATA), Adverse Outcome Pathway (AOP) frameworks and next generation risk assessment (NGRA). This review critically evaluates the scientific basis, technological platforms, translational applications, advantages, limitations and regulatory readiness of NAMs in modern toxicology. Particular emphasis is placed on the integration of human cell-based systems, microphysiological systems, organoids, transcriptomics, metabolomics, physiologically based kinetic (PBK) modelling, in vitro to in vivo extrapolation (IVIVE), exposure bioactivity relationships and scientific confidence frameworks. Current developments from the European Food Safety Authority (EFSA), European Chemicals Agency (ECHA), European Medicines Agency (EMA), Organisation for Economic Co-operation and Development (OECD), United States Food and Drug Administration (FDA), Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), Health Canada and the European Commission are discussed to highlight the increasing regulatory momentum toward fit-for-purpose qualification and reduced animal use. The review concludes that successful implementation of NAMs will require clear problem formulation, standardized reporting, robust quality control, uncertainty characterization, interoperable data infrastructures and international harmonization.

Journal of Research in PharmacyVol. 30(6)
Yeditepe University (TR), Gebze Technical University (TR), Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (TR)
Good health and well-being
Animal testing and alternatives
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon